Literature DB >> 28222513

Clinical Effectiveness and Tolerability of Electroconvulsive Therapy in Patients with Neuropsychiatric Symptoms of Dementia.

Moshe Isserles1,2, Zafiris J Daskalakis1,2, Sanjeev Kumar1,2,3, Tarek K Rajji1,2,3, Daniel M Blumberger1,2,3.   

Abstract

BACKGROUND: Dementia frequently presents with aggression, agitation, and disorganized behavior for which current treatment is partially effective and is associated with significant adverse effects.
OBJECTIVE: The aim of this study was to retrospectively assess the clinical effectiveness and tolerability of electroconvulsive therapy (ECT) in a sample of patients with neuropsychiatric symptoms of dementia (NPS) and to explore factors associated with response and with cognitive adverse effects.
METHODS: We examined the clinical records of 25 patients with dementia and a pre-existing psychiatric disorder treated with ECT at an academic mental health hospital between April 1, 2010 and January 28, 2016. Twenty-nine acute ECT courses and fifteen maintenance courses were reviewed. We assessed treatment effectiveness and cognitive adverse effects as well as factors associated with response to treatment, including pre-existing psychiatric disorders, concomitant pharmacological treatment and types of dementia.
RESULTS: ECT resulted in a clinically meaningful response in 72% of acute treatment courses. Cognitive adverse effects affecting functioning were reported in 7% of the acute treatment courses. Maintenance treatment was effective in sustaining the response in 87% of treatment courses with two reports of significant cognitive adverse effects. One patient fell and experienced a hip fracture a day after treatment. Use of antipsychotic or antidepressant medications, pre-existing psychiatric disorder, or gender were not associated with response.
CONCLUSION: This study shows meaningful clinical effectiveness and good tolerability of ECT in patients with severe NPS of dementia. Furthermore, maintenance ECT was effective in sustaining treatment response.

Entities:  

Keywords:  Alzheimer’s disease; dementia; electroconvulsive therapy; neuropsychiatric symptoms

Mesh:

Substances:

Year:  2017        PMID: 28222513     DOI: 10.3233/JAD-161000

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

Review 1.  Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.

Authors:  Milagros Rojas; Daniela Ariza; Ángel Ortega; Manuel E Riaño-Garzón; Mervin Chávez-Castillo; José Luis Pérez; Lorena Cudris-Torres; María Judith Bautista; Oscar Medina-Ortiz; Joselyn Rojas-Quintero; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

2.  Simulated Electroconvulsive Therapy: A Novel Approach to a Control Group in Clinical Trials.

Authors:  Kaitlin R McManus; Maria I Lapid; Brent P Forester; Martina Mueller; Adriana P Hermida; Louis Nykamp; David G Harper; Stephen J Seiner; Sohag Sanghani; Regan Patrick; Melanie T Gentry; Simon Kung; Janette C Leal; Emily K Johnson; Georgios Petrides
Journal:  J ECT       Date:  2022-03-01       Impact factor: 3.692

3.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

4.  Clinical Effectiveness of Maintenance Electroconvulsive Therapy in Patients with Schizophrenia: A Retrospective Cohort Study.

Authors:  Moshe Isserles; Jesse Remington; Tyler S Kaster; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  J ECT       Date:  2020-03       Impact factor: 3.692

5.  Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.

Authors:  Simon Jc Davies; Amer M Burhan; Donna Kim; Philip Gerretsen; Ariel Graff-Guerrero; Vincent L Woo; Sanjeev Kumar; Sarah Colman; Bruce G Pollock; Benoit H Mulsant; Tarek K Rajji
Journal:  J Psychopharmacol       Date:  2018-01-17       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.